Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu, Do‐Youn Oh, Sang Cheul Oh, Hyun Cheol Chung, Keun-Wook Lee, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Ik‐Joo Chung, Kensei Yamaguchi, Ken Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jen‐Shi Chen, Li‐Yuan Bai, Sung‐Yong Oh, Yasuhiro Choda, Hisateru Yasui, Kentaro Takeuchi, Yoshinori Hirashima, Shunsuke Hagihara, Narikazu Boku